These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 4361727)

  • 41. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV.
    Bakker WA; Thomassen YE; van't Oever AG; Westdijk J; van Oijen MG; Sundermann LC; van't Veld P; Sleeman E; van Nimwegen FW; Hamidi A; Kersten GF; van den Heuvel N; Hendriks JT; van der Pol LA
    Vaccine; 2011 Sep; 29(41):7188-96. PubMed ID: 21651934
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neutralizing capacity of poliovirus type 3 antibodies tested against 5 different intratypic variants of poliovirus type 3. A comparative study in children immunized with live, inactivated, or both types of poliovirus vaccines.
    Böttiger M
    Arch Gesamte Virusforsch; 1971; 35(2):251-5. PubMed ID: 4332939
    [No Abstract]   [Full Text] [Related]  

  • 43. Intestinal immunity induced by inactivated poliovirus vaccine.
    Selvakumar R; John TJ
    Vaccine; 1987 Jun; 5(2):141-4. PubMed ID: 3037815
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of injected and oral polio vaccine for booster immunization during the 1979 polio outbreak in Lancaster County, Pennsylvania.
    Doe RG; Kleger B; Randall JL
    Infect Control; 1981; 2(5):377-9. PubMed ID: 6271701
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group.
    Modlin JF; Halsey NA; Thoms ML; Meschievitz CK; Patriarca PA
    J Infect Dis; 1997 Feb; 175 Suppl 1():S228-34. PubMed ID: 9203721
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.
    Yang C; Shi H; Zhou J; Liang Y; Xu H
    Vaccine; 2009 Nov; 27(47):6558-63. PubMed ID: 19729087
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessment of efficacy of a live oral poliovirus vaccine for virulent Sabin-like poliovirus 1 strains in Japan.
    Iwai M; Nakayama T; Matsuura K; Hasegawa S; Ando S; Obara M; Nagai Y; Yoshida H; Horie H
    Acta Virol; 2006; 50(2):139-43. PubMed ID: 16808333
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains.
    Kersten G; Hazendonk T; Beuvery C
    Vaccine; 1999 Apr; 17(15-16):2059-66. PubMed ID: 10217607
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pathogenic Events in a Nonhuman Primate Model of Oral Poliovirus Infection Leading to Paralytic Poliomyelitis.
    Shen L; Chen CY; Huang D; Wang R; Zhang M; Qian L; Zhu Y; Zhang AZ; Yang E; Qaqish A; Chumakov K; Kouiavskaia D; Vignuzzi M; Nathanson N; Macadam AJ; Andino R; Kew O; Xu J; Chen ZW
    J Virol; 2017 Jul; 91(14):. PubMed ID: 28356537
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibody status to poliomyelitis, measles, rubella, diphtheria and tetanus, Ontario, 1969-70: deficiencies discovered and remedies required.
    MacLeod DR; Ing WK; Belcourt RJ; Pearson EW; Bell JS
    Can Med Assoc J; 1975 Oct; 113(7):619-23. PubMed ID: 1181016
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.
    Verdijk P; Rots NY; van Oijen MG; Oberste MS; Boog CJ; Okayasu H; Sutter RW; Bakker WA
    Vaccine; 2013 Nov; 31(47):5531-6. PubMed ID: 24063976
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Limited trafficking of a neurotropic virus through inefficient retrograde axonal transport and the type I interferon response.
    Lancaster KZ; Pfeiffer JK
    PLoS Pathog; 2010 Mar; 6(3):e1000791. PubMed ID: 20221252
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunization against poliomyelitis: risk/benefit/cost in a changing context.
    Salk J
    Dev Biol Stand; 1979; 43():151-7. PubMed ID: 230106
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines.
    McBean AM; Thoms ML; Albrecht P; Cuthie JC; Bernier R
    Am J Epidemiol; 1988 Sep; 128(3):615-28. PubMed ID: 2843039
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial.
    Liao G; Li R; Li C; Sun M; Li Y; Chu J; Jiang S; Li Q
    J Infect Dis; 2012 Jan; 205(2):237-43. PubMed ID: 22158682
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Production of high titer attenuated poliovirus strains on the serum-free PER.C6(®) cell culture platform for the generation of safe and affordable next generation IPV.
    Sanders BP; Oakes Ide L; van Hoek V; Liu Y; Marissen W; Minor PD; Wimmer E; Schuitemaker H; Custers JH; Macadam A; Cello J; Edo-Matas D
    Vaccine; 2015 Nov; 33(48):6611-6. PubMed ID: 26529068
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials.
    Sáez-Llorens X; Bandyopadhyay AS; Gast C; Leon T; DeAntonio R; Jimeno J; Caballero MI; Aguirre G; Oberste MS; Weldon WC; Konopka-Anstadt JL; Modlin J; Bachtiar NS; Fix A; Konz J; Clemens R; Costa Clemens SA; Rüttimann R
    Lancet; 2021 Jan; 397(10268):27-38. PubMed ID: 33308427
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intestinal trypsin can significantly modify antigenic properties of polioviruses: implications for the use of inactivated poliovirus vaccine.
    Roivainen M; Hovi T
    J Virol; 1987 Dec; 61(12):3749-53. PubMed ID: 2824812
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Limited genetic changes in the Sabin 1 strain of poliovirus occurring in the central nervous system of monkeys.
    Lu Z; Rezapkin GV; Douthitt MP; Ran Y; Asher DM; Levenbook IS; Chumakov KM
    J Gen Virol; 1996 Feb; 77 ( Pt 2 )():273-80. PubMed ID: 8627231
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase 3 Trial of a Sabin Strain-Based Inactivated Poliovirus Vaccine.
    Liao G; Li R; Li C; Sun M; Jiang S; Li Y; Mo Z; Xia J; Xie Z; Che Y; Yang J; Yin Z; Wang J; Chu J; Cai W; Zhou J; Wang J; Li Q
    J Infect Dis; 2016 Dec; 214(11):1728-1734. PubMed ID: 27658691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.